Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies.

التفاصيل البيبلوغرافية
العنوان:	Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies.
المؤلفون:	Jongbloed M; Department of Pulmonary Diseases, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., Khosla AA; Division of Internal Medicine, William Beaumont University Hospital, Royal Oak, MI, USA., Bartolomeo V; Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; Department of Clinical Surgical, Diagnostic and Pediatric Sciences, Pavia University, Pavia, Italy.; Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, GROW School for Oncology and Reproduction (GROW), Maastricht, Netherlands., Jatwani K; Division of Hematology-Oncology, Roswell Park Cancer Center, Buffalo, NY, USA., Singh R; Division of Hematology-Oncology, University of Vermont, Burlington, VT, USA., De Ruysscher DKM; Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, GROW School for Oncology and Reproduction (GROW), Maastricht, Netherlands., Hendriks LEL; Department of Pulmonary Diseases, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., Desai A; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, 1824 6th Ave S, Birmingham, AL, 35233, USA. aakashdesai@uabmc.edu.
المصدر:	Current oncology reports [Curr Oncol Rep] 2024 Jan; Vol. 26 (1), pp. 80-89. Date of Electronic Publication: 2024 Jan 02.
نوع المنشور:	Journal Article; Review
اللغة:	English
بيانات الدورية:	Publisher: Current Science Country of Publication: United States NLM ID: 100888967 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6269 (Electronic) Linking ISSN: 15233790 NLM ISO Abbreviation: Curr Oncol Rep Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Philadelphia, PA : Current Science, c1999-
مواضيع طبية MeSH:	Lung Neoplasms/drug therapy , Carcinoma, Non-Small-Cell Lung/pathology , Radiosurgery*, Humans ; Disease Progression ; Immunotherapy
مستخلص:	Purpose of Review: This review discusses the definitions, treatment modalities, management, future directions, and ongoing clinical trials of oligoprogressive disease in oncogene-driven and non-oncogene-driven NSCLC. Recent Findings: During the last decades, diagnostic and treatment modalities for oligometastatic NSCLC have advanced significantly, leading to improved survival. Additionally, our understanding of the tumor biology of oligoprogressive disease has expanded. However, despite the efforts of organizations, such as EORTC, ESTRO, and ASTRO proposing definitions for oligometastatic and oligoprogressive disease, heterogeneity in definitions persists in (ongoing) trials. Recognizing the significance of subclassification within oligoprogressive disease in NSCLC and the varying risks associated with subsequent metastatic spread, there is a call for tailored management strategies. A consensus on standardized criteria for the definition of oligoprogressive disease is urgently needed and will not only facilitate meaningful comparisons between studies but also pave the way for the development of personalized treatment plans that take into account the heterogeneous nature of oligoprogressive disease. (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References:	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 . (PMID: 10.3322/caac.2166033538338) Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262 . (PMID: 10.3322/caac.2126225651787) Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403. https://doi.org/10.1016/j.ejca.2012.12.027 . (PMID: 10.1016/j.ejca.2012.12.02723485231) Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. https://doi.org/10.1200/jco.1995.13.1.8 . (PMID: 10.1200/jco.1995.13.1.87799047) Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. Radiotherapy for oligometastatic lung cancer. Front Oncol. 2017;7:210. https://doi.org/10.3389/fonc.2017.00210 . (PMID: 10.3389/fonc.2017.00210289750815610690) De Ruysscher D, Wanders R, Hendriks LE, van Baardwijk A, Reymen B, Houben R, et al. Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450). J Thorac Oncol. 2018;13(12):1958–61. https://doi.org/10.1016/j.jtho.2018.07.098 . (PMID: 10.1016/j.jtho.2018.07.09830253974) Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501. https://doi.org/10.1001/jamaoncol.2017.3501 . (PMID: 10.1001/jamaoncol.2017.350128973074) Griffioen GH, Toguri D, Dahele M, Warner A, de Haan PF, Rodrigues GB, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer. 2013;82(1):95–102. https://doi.org/10.1016/j.lungcan.2013.07.023 . (PMID: 10.1016/j.lungcan.2013.07.02323973202) Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012;7(2):376–81. https://doi.org/10.1097/JTO.0b013e31824166a5 . (PMID: 10.1097/JTO.0b013e31824166a522198429) Berzenji L, Debaenst S, Hendriks JMH, Yogeswaran SK, Lauwers P, Van Schil PE. The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review. Transl Lung Cancer Res. 2021;10(7):3409–19. https://doi.org/10.21037/tlcr-21-58 . (PMID: 10.21037/tlcr-21-58344303768350094) Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, et al. Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report. J Thorac Oncol. 2019;14(12):2109–19. https://doi.org/10.1016/j.jtho.2019.07.025 . (PMID: 10.1016/j.jtho.2019.07.02531398540) Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28. https://doi.org/10.1016/s1470-2045(19)30718-1 . (PMID: 10.1016/s1470-2045(19)30718-131908301) Lanuti M. Surgical management of oligometastatic non-small cell lung cancer. Thorac Surg Clin. 2016;26(3):287–94. https://doi.org/10.1016/j.thorsurg.2016.04.002 . (PMID: 10.1016/j.thorsurg.2016.04.00227427523) Willmann J, Vlaskou Badra E, Adilovic S, Ahmadsei M, Christ SM, van Timmeren JE, et al. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study. Radiother Oncol. 2022;168:256–64. https://doi.org/10.1016/j.radonc.2022.01.019 . (PMID: 10.1016/j.radonc.2022.01.01935101466) Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014;15(5):346–55. https://doi.org/10.1016/j.cllc.2014.04.003 . (PMID: 10.1016/j.cllc.2014.04.00324894943) Harada D, Takigawa N. Oligoprogression in Non-Small Cell Lung Cancer. Cancers (Basel). 2021;13(22) https://doi.org/10.3390/cancers13225823 . Basler L, Kroeze SG, Guckenberger M. SBRT for oligoprogressive oncogene addicted NSCLC. Lung Cancer. 2017;106:50–7. https://doi.org/10.1016/j.lungcan.2017.02.007 . (PMID: 10.1016/j.lungcan.2017.02.00728285694) Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14. https://doi.org/10.1097/JTO.0b013e3182745948 . (PMID: 10.1097/JTO.0b013e3182745948231545523506112) Al-Halabi H, Sayegh K, Digamurthy SR, Niemierko A, Piotrowska Z, Willers H, et al. Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol. 2015;10(11):1601–7. https://doi.org/10.1097/jto.0000000000000648 . (PMID: 10.1097/jto.000000000000064826313684) Heo JY, Yoo SH, Suh KJ, Kim SH, Kim YJ, Ock CY, et al. Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients. Sci Rep. 2021;11(1):2514. https://doi.org/10.1038/s41598-021-81666-x . (PMID: 10.1038/s41598-021-81666-x335102557844257) Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, et al. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. BMC Cancer. 2021;21(1):346. https://doi.org/10.1186/s12885-021-08048-4 . (PMID: 10.1186/s12885-021-08048-4337948098017679) Rheinheimer S, Heussel CP, Mayer P, Gaissmaier L, Bozorgmehr F, Winter H, et al. Oligoprogressive non-small-cell lung cancer under treatment with PD-(L)1 inhibitors. Cancers (Basel). 2020;12(4) https://doi.org/10.3390/cancers12041046 . Wang Z, Wei L, Li J, Zhou H, Li S, Chen D, et al. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(12):4368–79. https://doi.org/10.21037/tlcr-21-682 . (PMID: 10.21037/tlcr-21-682350707478743519) Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014;88(4):892–8. https://doi.org/10.1016/j.ijrobp.2013.11.010 . (PMID: 10.1016/j.ijrobp.2013.11.010244623834160890) Kagawa Y, Furuta H, Uemura T, Watanabe N, Shimizu J, Horio Y, et al. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer. Cancer Sci. 2020;111(12):4442–52. https://doi.org/10.1111/cas.14605 . (PMID: 10.1111/cas.14605327706087734009) Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, et al. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun. 2019;19:100126. https://doi.org/10.1016/j.ctarc.2019.100126 . (PMID: 10.1016/j.ctarc.2019.10012630852467) Tumati V, Iyengar P. The current state of oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Dis. 2018;10(Suppl 21):S2537–s44. https://doi.org/10.21037/jtd.2018.07.19 . (PMID: 10.21037/jtd.2018.07.19302064976123193) Martínez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature. 2023;616(7957):543–52. https://doi.org/10.1038/s41586-023-05706-4 . (PMID: 10.1038/s41586-023-05706-43704609310115639) Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. https://doi.org/10.1126/scitranslmed.3002003 . (PMID: 10.1126/scitranslmed.3002003214302693132801) Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A. Role of local ablative therapy in patients with oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Oncol. 2017;12(2):179–93. https://doi.org/10.1016/j.jtho.2016.10.012 . (PMID: 10.1016/j.jtho.2016.10.01227780780) Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–43. https://doi.org/10.1126/science.1141478 . (PMID: 10.1126/science.114147817463250) Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 2011;6(12):2011–7. https://doi.org/10.1097/JTO.0b013e31823ab0dd . (PMID: 10.1097/JTO.0b013e31823ab0dd22052230) Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023;616(7957):525–33. https://doi.org/10.1038/s41586-023-05783-5 . (PMID: 10.1038/s41586-023-05783-53704609610115649) Belluomini L, Dodi A, Caldart A, Kadrija D, Sposito M, Casali M, et al. A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done. Transl Lung Cancer Res. 2021;10(7):3369–84. https://doi.org/10.21037/tlcr-20-1134 . (PMID: 10.21037/tlcr-20-1134344303738350097) Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol. 2009;4(7):809–15. https://doi.org/10.1097/JTO.0b013e3181a94af4 . (PMID: 10.1097/JTO.0b013e3181a94af419487967) Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105–17. https://doi.org/10.1016/j.bbcan.2009.11.002 . (PMID: 10.1016/j.bbcan.2009.11.00219931353) Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11. https://doi.org/10.1038/35102167 . (PMID: 10.1038/3510216711689955) Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012;13(4):e178–85. https://doi.org/10.1016/s1470-2045(11)70335-7 . (PMID: 10.1016/s1470-2045(11)70335-722469128) Nguyen KT, Sakthivel G, Milano MT, Qiu H, Singh DP. Oligoprogression in non-small cell lung cancer: a narrative review. J Thorac Dis. 2022;14(12):4998–5011. https://doi.org/10.21037/jtd-22-536 . (PMID: 10.21037/jtd-22-536366475029840049) Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012;118(18):4502–11. https://doi.org/10.1002/cncr.27409 . (PMID: 10.1002/cncr.2740922282022) NCCN: NCCN guidelines non-small cell lung cancer. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 (2023). Accessed May 2, 2023. Liam CK. Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer. Ann Transl Med. 2019;7(3):61. https://doi.org/10.21037/atm.2018.12.68 . (PMID: 10.21037/atm.2018.12.68309067656389567) Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830–8. https://doi.org/10.1200/jco.20.00818 . (PMID: 10.1200/jco.20.00818324847547460150) Tsai CJ, Yang JT, Guttmann DM, Shaverdian N, Shepherd AF, Eng J, et al. Consolidative use of radiotherapy to block (CURB) oligoprogression ― Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast. Int J Radiat Oncol Biol Phys. 2021;111(5):1325–6. https://doi.org/10.1016/j.ijrobp.2021.09.014 . (PMID: 10.1016/j.ijrobp.2021.09.014) Holt C. Radiation therapy in oligoprogressive NSCLC & breast cancer. Oncology Times. 2022;44(3). Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer. 2012;75(1):9–14. https://doi.org/10.1016/j.lungcan.2011.07.014 . (PMID: 10.1016/j.lungcan.2011.07.01421864934) Handy JR, Bremner RM, Crocenzi TS, Detterbeck FC, Fernando HC, Fidias PM, et al. Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg. 2019;107(2):631–49. https://doi.org/10.1016/j.athoracsur.2018.10.028 . (PMID: 10.1016/j.athoracsur.2018.10.02830476477) Okubo K, Bando T, Miyahara R, Sakai H, Shoji T, Sonobe M, et al. Resection of pulmonary metastasis of non-small cell lung cancer. J Thorac Oncol. 2009;4(2):203–7. https://doi.org/10.1097/JTO.0b013e3181949c6a . (PMID: 10.1097/JTO.0b013e3181949c6a19179897) Ileana E, Greillier L, Moutardier V, Barlesi F. Surgical resection of liver non-small cell lung cancer metastasis: a dual weapon? Lung Cancer. 2010;70(2):221–2. https://doi.org/10.1016/j.lungcan.2010.08.010 . (PMID: 10.1016/j.lungcan.2010.08.01020828859) Nagashima A, Abe Y, Yamada S, Nakagawa M, Yoshimatsu T. Long-term survival after surgical resection of liver metastasis from lung cancer. Jpn J Thorac Cardiovasc Surg. 2004;52(6):311–3. https://doi.org/10.1007/s11748-004-0050-y . (PMID: 10.1007/s11748-004-0050-y15242087) Ercolani G, Ravaioli M, Grazi GL, Cescon M, Varotti G, Del Gaudio M, et al. The role of liver resections for metastases from lung carcinoma. HPB (Oxford). 2006;8(2):114–5. https://doi.org/10.1080/13651820500471970 . (PMID: 10.1080/1365182050047197018333258) Ambrogi V, Nofroni I, Tonini G, Mineo TC. Skin metastases in lung cancer: analysis of a 10-year experience. Oncol Rep. 2001;8(1):57–61. (PMID: 11115569) Agarwala AK, Hanna NH. Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy. Clin Lung Cancer. 2005;6(6):367–8. https://doi.org/10.3816/CLC.2005.n.017 . (PMID: 10.3816/CLC.2005.n.01715943898) Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358–76. https://doi.org/10.1016/j.annonc.2022.12.013 . (PMID: 10.1016/j.annonc.2022.12.01336669645) Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497–530. https://doi.org/10.6004/jnccn.2022.0025 . (PMID: 10.6004/jnccn.2022.002535545176) Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339–57. https://doi.org/10.1016/j.annonc.2022.12.009 . (PMID: 10.1016/j.annonc.2022.12.00936872130) Xu Q, Liu H, Meng S, Jiang T, Li X, Liang S, et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer. 2019;10(2):522–9. https://doi.org/10.7150/jca.26494 . (PMID: 10.7150/jca.26494307191486360299) Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–51. https://doi.org/10.1097/JTO.0b013e31827e1f83 . (PMID: 10.1097/JTO.0b013e31827e1f83234075583673295) Shukuya T, Takahashi T, Naito T, Kaira R, Ono A, Nakamura Y, et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer. 2011;74(3):457–61. https://doi.org/10.1016/j.lungcan.2011.04.007 . (PMID: 10.1016/j.lungcan.2011.04.00721571388) Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014;3:e28518. https://doi.org/10.4161/onci.28518 . (PMID: 10.4161/onci.28518250719794106151) Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1611–8. https://doi.org/10.1200/jco.2017.76.2229 . (PMID: 10.1200/jco.2017.76.2229294375355978468) Xu Y, Li H, Fan Y. Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer. Front Oncol. 2021;11:642883. https://doi.org/10.3389/fonc.2021.642883 . (PMID: 10.3389/fonc.2021.642883337479667973268) Qiu B, Liang Y, Li Q, Liu G, Wang F, Chen Z, et al. Local therapy for oligoprogressive disease in patients with advanced stage non-small-cell lung cancer harboring epidermal growth factor receptor mutation. Clin Lung Cancer. 2017;18(6):e369–e73. https://doi.org/10.1016/j.cllc.2017.04.002 . (PMID: 10.1016/j.cllc.2017.04.00228465010) Niu L, Chen J, Yao F, Zhou L, Zhang C, Wen W, et al. Percutaneous cryoablation for stage IV lung cancer: a retrospective analysis. Cryobiology. 2013;67(2):151–5. https://doi.org/10.1016/j.cryobiol.2013.06.005 . (PMID: 10.1016/j.cryobiol.2013.06.00523806858) Hiraki T, Tajiri N, Mimura H, Yasui K, Gobara H, Mukai T, et al. Pneumothorax, pleural effusion, and chest tube placement after radiofrequency ablation of lung tumors: incidence and risk factors. Radiology. 2006;241(1):275–83. https://doi.org/10.1148/radiol.2411051087 . (PMID: 10.1148/radiol.241105108716908680) McDevitt JL, Mouli SK, Nemcek AA, Lewandowski RJ, Salem R, Sato KT. Percutaneous cryoablation for the treatment of primary and metastatic lung tumors: identification of risk factors for recurrence and major complications. J Vasc Interv Radiol. 2016;27(9):1371–9. https://doi.org/10.1016/j.jvir.2016.04.005 . (PMID: 10.1016/j.jvir.2016.04.00527321886) Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC. J Natl Cancer Inst. 2022; https://doi.org/10.1093/jnci/djac015 . Xu Q, Zhou F, Liu H, Jiang T, Li X, Xu Y, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol. 2018;13(9):1383–92. https://doi.org/10.1016/j.jtho.2018.05.019 . (PMID: 10.1016/j.jtho.2018.05.01929852232) Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–67. https://doi.org/10.1016/s1470-2045(18)30649-1 . (PMID: 10.1016/s1470-2045(18)30649-130413378) Takeda M, Okamoto I, Nakagawa K. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol. 2013;8(5):654–7. https://doi.org/10.1097/JTO.0b013e31828c28e7 . (PMID: 10.1097/JTO.0b013e31828c28e723584297) Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881–8. https://doi.org/10.1200/jco.2014.59.0539 . (PMID: 10.1200/jco.2014.59.0539256244364451171) Robin TP, Camidge DR, Stuhr K, Nath SK, Breeze RE, Pacheco JM, et al. Excellent outcomes with radiosurgery for multiple brain metastases in ALK and EGFR driven non-small cell lung cancer. J Thorac Oncol. 2018;13(5):715–20. https://doi.org/10.1016/j.jtho.2017.12.006 . (PMID: 10.1016/j.jtho.2017.12.00629269007) Zhao Y, Zhang B, Wang S, Qiao R, Xu J, Zhang L, et al. Management of central nervous system metastases in patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer during crizotinib treatment. Clin Lung Cancer. 2019;20(6):e631–e7. https://doi.org/10.1016/j.cllc.2019.06.013 . (PMID: 10.1016/j.cllc.2019.06.01331362880) Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–40. https://doi.org/10.1158/1078-0432.Ccr-16-0399 . (PMID: 10.1158/1078-0432.Ccr-16-039927435396) Huang YH, Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY, et al. The difference in clinical outcomes between osimertinib and afatinib for first-line treatment in patients with advanced and recurrent EGFR-mutant non-small cell lung cancer in Taiwan. Target Oncol. 2022;17(3):295–306. https://doi.org/10.1007/s11523-022-00878-x . (PMID: 10.1007/s11523-022-00878-x354604749633524) Gen S, Tanaka I, Morise M, Koyama J, Kodama Y, Matsui A, et al. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. BMC Cancer. 2022;22(1):654. https://doi.org/10.1186/s12885-022-09741-8 . (PMID: 10.1186/s12885-022-09741-8356980839195197) Zhou Y, Wang B, Qu J, Yu F, Zhao Y, Li S, et al. Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: osimertinib vs. first-generation EGFR tyrosine kinase inhibitors. Lung Cancer. 2020;150:178–85. https://doi.org/10.1016/j.lungcan.2020.10.018 . (PMID: 10.1016/j.lungcan.2020.10.01833186860) Zhao Y, Li S, Yang X, Chu L, Wang S, Tong T, et al. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis. Int J Cancer. 2022;150(8):1318–28. https://doi.org/10.1002/ijc.33904 . (PMID: 10.1002/ijc.3390434914096) Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 2023;41(2):385–94. https://doi.org/10.1200/jco.22.00393 . (PMID: 10.1200/jco.22.0039336122315) Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22(7):959–69. https://doi.org/10.1016/s1470-2045(21)00247-3 . (PMID: 10.1016/s1470-2045(21)00247-334118197) Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res. 2022;28(8):1482–6. https://doi.org/10.1158/1078-0432.Ccr-21-3074 . (PMID: 10.1158/1078-0432.Ccr-21-3074349035829012672) Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371–81. https://doi.org/10.1056/NEJMoa2103695 . (PMID: 10.1056/NEJMoa2103695340966909116274) Ai X, Wang Q, Cheng Y, Liu X, Cao L, Chen J, et al. Safety but limited efficacy of ensartinib in ROS1-positive NSCLC: a single-arm, multicenter phase 2 study. J Thorac Oncol. 2021;16(11):1959–63. https://doi.org/10.1016/j.jtho.2021.06.023 . (PMID: 10.1016/j.jtho.2021.06.02334265433) Drilon A, Chiu CH, Fan Y, Cho BC, Lu S, Ahn MJ, et al. Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC. JTO Clin Res Rep. 2022;3(6):100332. https://doi.org/10.1016/j.jtocrr.2022.100332 . (PMID: 10.1016/j.jtocrr.2022.100332356634149160474)
فهرسة مساهمة:	Keywords: Definition; Local radical therapy; NSCLC; Oligometastatic disease; Oligoprogressive disease; Treatment strategies
تواريخ الأحداث:	Date Created: 20240104 Date Completed: 20240214 Latest Revision: 20240529
رمز التحديث:	20240530
DOI:	10.1007/s11912-023-01490-6
PMID:	38175464
قاعدة البيانات:	MEDLINE

Find this article in full text from Springer Verlag.

Full Text Finder

الوصف
تدمد:	1534-6269
DOI:	10.1007/s11912-023-01490-6